Point6 Bio
Biomarker-based Analysis for Diagnostics of Autism
Company Overview
Snapshot
Founded in January 2023 by Neta Barashi, Point6 Bio operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing biomarker-based diagnostics for Autism.
Business overview
Point6 Bio is a computational biology company that captures multi-omics molecular insights from the proteome, including the gut microbiome, to identify biomarker signatures for Autism. Its platform integrates advanced AI with multi-omic data to detect molecular changes underlying neurodevelopmental disorders. By decoding proteomic and post-translational modification patterns from blood samples, the company aims to enable early, reliable diagnosis and transform Autism Spectrum Disorder (ASD) care, serving the healthcare and life sciences sectors.
Log in to access full profile ›Company Intelligence Q&A
- What is Point6 Bio's primary focus?
- Point6 Bio focuses on computational biology, specifically on capturing multi-omics molecular insights to identify biomarker signatures for the diagnostics of Autism.
- When was Point6 Bio founded?
- Point6 Bio was founded in January 2023.
- Who is a co-founder of Point6 Bio?
- Neta Barashi is a co-founder and CEO of Point6 Bio.
- What technology does Point6 Bio utilize?
- Point6 Bio's platform integrates advanced AI with multi-omic data to detect molecular changes underlying neurodevelopmental disorders.
- What is Point6 Bio's product stage?
- Point6 Bio is currently in the R&D stage for its product development.